Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Patient Name
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Anti-Inflammatory Properties of a Processed Copper Complex in L-Arginine Induced Pancreatitis-Two Experimental Studies
Recurrent Acute/Chronic Pancreatitis (RA/CP) is a progressive pancreatic inflammation, often with unclear causes. An Ayurvedic Mineral Complex (AMC) showed promise in reducing exacerbations and hospitalizations in pancreatitis patients. In a rat model, AMC was well tolerated, reduced oxidative stress and inflammation, and protected the pancreas at doses of 25 mg/kg and 19 mg/kg.
Proof of Efficacy Study to Evaluate an Ayurvedic Formulation in the Treatment of Allergic Rhinitis: An Open Label Randomized Controlled Clinical Trial
A study on 250 patients compared the Ayurvedic formulation IMMBO to a levocetirizine-montelukast combination for allergic rhinitis. IMMBO showed significantly greater improvements in symptoms (TNSS: -5.70 vs. -3.31) and IgE reduction (-351.54 vs. -208.79), demonstrating superior efficacy and safety.
Acute and Sub acute Toxicity Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
This study tested the safety of five Ayurvedic formulations for migraine prevention in rats and mice. Acute and sub-acute toxicity studies showed no toxic effects at doses up to 10 times the human dose. A slight mortality in high-dose groups was unrelated to treatment. The formulations are considered safe, but further chronic toxicity studies are needed.
Randomized Controlled Study to Evaluate Prophylactic Properties of Ayurvedic Treatment Protocol in Refractory and Chronic Migraine Patients
This study compared Ayurvedic treatment to conventional therapy for chronic refractory migraine. After 360 days, the Ayurvedic group showed greater reductions in headache days, VAS, and MIDAS scores (p
Ayurvedic preparation in the treatment of nutritional anemia
A pilot study on 600 anemic women showed the highest hemoglobin gain (1.8 g%) with a combination of Ayurvedic preparations SS and Ayas, followed by Ayas (1.6 g%), SS (1.5 g%), and IFA tablets (1.1 g%). SS, a non-iron Ayurvedic preparation, improved iron absorption and showed promising results with minimal side effects.
Clinical Intervention of Ayurvedic Treatment in the Patients of Recurrent Acute/Chronic Pancreatitis
The study of 1233 acute pancreatitis patients found that 12.9% experienced oral feeding intolerance (OFI). Risk factors included younger age, male sex, alcohol use, smoking, non-biliary etiology, and SIRS at 48h. SIRS at 48h (OR 2.85) and non-biliary etiology (OR 1.77) were independently linked to OFI, with biliary etiology being protective.